Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2012 2
2013 1
2016 1
2018 1
2019 1
2020 1
2021 2
2022 1
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.
EINSTEIN–PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. EINSTEIN–PE Investigators, et al. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26. N Engl J Med. 2012. PMID: 22449293 Free article. Clinical Trial.
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of pulmonary embolism and had a potentially improved benefit-risk profile. ...
CONCLUSIONS: A fixed-dose regimen of rivaroxaban alone was noninferior to standard therapy for the initial and long-term treatment of …
Long-term outcome of pulmonary embolism.
Meyer G, Planquette B, Sanchez O. Meyer G, et al. Among authors: planquette b. Curr Opin Hematol. 2008 Sep;15(5):499-503. doi: 10.1097/MOH.0b013e3283063a51. Curr Opin Hematol. 2008. PMID: 18695374 Review.
PURPOSE OF REVIEW: Until recently, little was known about the long-term outcome of pulmonary embolism. Long-term mortality and recurrence rates, the case fatality rate of recurrent events, and the frequency of persistent vascular defects remained largely unknown. Im …
PURPOSE OF REVIEW: Until recently, little was known about the long-term outcome of pulmonary embolism. Long-term mortality and …
From Acute to Chronic Thromboembolic Disease.
Fernandes T, Planquette B, Sanchez O, Morris T. Fernandes T, et al. Among authors: planquette b. Ann Am Thorac Soc. 2016 Jul;13 Suppl 3:S207-14. doi: 10.1513/AnnalsATS.201509-619AS. Ann Am Thorac Soc. 2016. PMID: 27571002 Review.
After achievement of adequate anticoagulation, the natural history of acute pulmonary emboli ranges from near total resolution of vascular perfusion to long-term persistence of hemodynamically consequential residual perfusion defects. ...
After achievement of adequate anticoagulation, the natural history of acute pulmonary emboli ranges from near total resolution of vascular p …
Triaging in pulmonary embolism.
Sanchez O, Planquette B, Roux A, Gosset-Woimant M, Meyer G. Sanchez O, et al. Among authors: planquette b. Semin Respir Crit Care Med. 2012 Apr;33(2):156-62. doi: 10.1055/s-0032-1311794. Epub 2012 May 30. Semin Respir Crit Care Med. 2012. PMID: 22648488
High-risk pulmonary embolism is defined by shock or peripheral signs of hypoperfusion. It is a life-threatening emergency with high short-term mortality (>25%) requiring specific therapeutic strategy with inotropic agents and fibrinolysis. ...
High-risk pulmonary embolism is defined by shock or peripheral signs of hypoperfusion. It is a life-threatening emergency with high short- …
Acute phase determinant of post-thrombotic syndrome: A review of the literature.
Khider L, Planquette B, Smadja DM, Sanchez O, Rial C, Goudot G, Messas E, Mirault T, Gendron N. Khider L, et al. Among authors: planquette b. Thromb Res. 2024 Apr 12;238:11-18. doi: 10.1016/j.thromres.2024.04.004. Online ahead of print. Thromb Res. 2024. PMID: 38643521 Review.
BACKGROUND: Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are being evaluated to prevent or to treat PTS. ...
BACKGROUND: Post-thrombotic syndrome (PTS) is the main long-term complication of deep vein thrombosis (DVT). Several therapies are be …
Chatbot-based serious games: A useful tool for training medical students? A randomized controlled trial.
Al Kahf S, Roux B, Clerc S, Bassehila M, Lecomte A, Moncomble E, Alabadan E, de Montmolin N, Jablon E, François E, Friedlander G, Badoual C, Meyer G, Roche N, Martin C, Planquette B. Al Kahf S, et al. Among authors: planquette b. PLoS One. 2023 Mar 13;18(3):e0278673. doi: 10.1371/journal.pone.0278673. eCollection 2023. PLoS One. 2023. PMID: 36913346 Free PMC article. Clinical Trial.
The CHATPROGRESS study aimed to evaluate the impact of Chatprogress on students' success rate in their end-term exams. METHODS: We conducted a post-test randomized controlled trial held on all fourth-year MS at Paris Descartes University. All MS were asked to follow the Un …
The CHATPROGRESS study aimed to evaluate the impact of Chatprogress on students' success rate in their end-term exams. METHODS: We co …
Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.
Planquette B, Sanchez O, Marsh JJ, Chiles PG, Emmerich J, Le Gal G, Meyer G, Wolfson T, Gamst AC, Moore RE, Gugiu GB, Morris TA. Planquette B, et al. Eur Respir J. 2018 Nov 15;52(5):1801467. doi: 10.1183/13993003.01467-2018. Print 2018 Nov. Eur Respir J. 2018. PMID: 30337447 Free PMC article.
Residual pulmonary vascular obstruction (RPVO) and chronic thromboembolic pulmonary hypertension (CTEPH) are both long-term complications of acute pulmonary embolism, but it is unknown whether RPVO can be predicted by variants of fibrinogen associated with CTEPH.We used th …
Residual pulmonary vascular obstruction (RPVO) and chronic thromboembolic pulmonary hypertension (CTEPH) are both long-term complicat …
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.
CORIMUNO-19 Collaborative group. CORIMUNO-19 Collaborative group. Lancet Rheumatol. 2022 Jan;4(1):e24-e32. doi: 10.1016/S2665-9913(21)00315-5. Epub 2021 Nov 17. Lancet Rheumatol. 2022. PMID: 34812424 Free PMC article.
Further studies are warranted to evaluate the effect of sarilumab on long-term survival. FUNDING: Assistance publique-Hopitaux de Paris....
Further studies are warranted to evaluate the effect of sarilumab on long-term survival. FUNDING: Assistance publique-Hopitaux de Par …
Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study.
Plaisance L, Chapelle C, Laporte S, Planquette B, Bertoletti L, Falvo N, Couturaud F, Falchero L, Mahé I, Helfer H, Dennaoui S, Meyer G, Mahé I. Plaisance L, et al. Among authors: planquette b. J Cancer Sci Clin Ther. 2021 Aug 11;5(3):347-362. doi: 10.26502/jcsct.5079122. J Cancer Sci Clin Ther. 2021. PMID: 37169025 Free PMC article.
Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study.
Mahé I, Plaisance L, Chapelle C, Laporte S, Planquette B, Bertoletti L, Couturaud F, Falvo N, Falchero L, Mahé I, Helfer H, Chidiac J, Meyer G. Mahé I, et al. Among authors: planquette b. Cancers (Basel). 2020 Aug 12;12(8):2256. doi: 10.3390/cancers12082256. Cancers (Basel). 2020. PMID: 32806574 Free PMC article.
13 results